SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Open Access
- 5 May 2022
- journal article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (18), 2200178-24
- https://doi.org/10.2807/1560-7917.es.2022.27.18.2200178
Abstract
Background Omicron subvariant BA.2 circulation is rapidly increasing globally. Aim We evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants. Methods Using 50% plaque reduction neutralisation tests (PRNT50), we assessed neutralising antibody titres to BA.2, wild type (WT) SARS-CoV-2 and other variants in Comirnaty or CoronaVac vaccinees, with or without prior WT-SARS-CoV-2 infection. Titres were also measured for non-vaccinees convalescing from a WT-SARS-CoV-2 infection. Neutralising antibodies in BA.2 and BA.1 breakthrough infections and in BA.2 infections affecting non-vaccinees were additionally studied. Results In vaccinees or prior WT-SARS-CoV-2-infected people, BA.2 and BA.1 PRNT50 titres were comparable but significantly (p < 10 − 5) lower than WT. In each group of 20 vaccinees with (i) three-doses of Comirnaty, (ii) two CoronaVac followed by one Comirnaty dose, or (iii) one dose of either vaccine after a WT-SARS-CoV-2 infection, ≥ 19 individuals developed detectable (PRNT50 titre ≥ 10) antibodies to BA.2, while only 15 of 20 vaccinated with three doses of CoronaVac did. Comirnaty vaccination elicited higher titres to BA.2 than CoronaVac. In people convalescing from a WT-SARS-CoV-2 infection, a single vaccine dose induced higher BA.2 titres than three Comirnaty (p = 0.02) or CoronaVac (p = 0.00001) doses in infection-naïve individuals. BA.2 infections in previously uninfected and unvaccinated individuals elicited low (PRNT50 titre ≤ 80) responses with little cross-neutralisation of other variants. However, vaccinees with BA.1 or BA.2 breakthrough infections had broad cross-neutralising antibodies to WT viruses, and BA.1, BA.2, Beta and Delta variants. Conclusions Existing vaccines can be of help against the BA.2 subvariant.Keywords
This publication has 24 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsThe New England Journal of Medicine, 2021
- Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong KongRespirology, 2021
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Nature, 2021
- Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protectionEClinicalMedicine, 2021
- Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent mannerCell Host & Microbe, 2021
- SARS-CoV-2 variants, spike mutations and immune escapeNature Reviews Microbiology, 2021
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodiesCell, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProceedings of the National Academy of Sciences of the United States of America, 2020